Abstract 6682: A patient-specific, tumor-informed, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assay in surgical patients with biliary tract cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6682
Abstract: Background: Biliary tract cancer (BTC) refers to malignancies arising from the bile ducts, gallbladder, and ampulla of Vater. ctDNA-based MRD testing has shown promise in identifying surgical patients at high risk of recurrence, although there… read more here.
Keywords: tumor informed; ctdna; patient specific; tumor ... See more keywords
Abstract LB293: The evolution of MRD assays: Moving beyond the tumor-Informed bespoke NGS panel
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb293
Abstract: The non-invasive detection of circulating tumor DNA (ctDNA) from plasma has been shown to have clinical value for detection of minimal residual disease (MRD), identification of emerging resistance to treatment, and predicting treatment response. The… read more here.
Keywords: tumor informed; panel; mrd; informed bespoke ... See more keywords
Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
Sign Up to like & getrecommendations! Published in 2023 at "EMBO molecular medicine"
DOI: 10.15252/emmm.202216505
Abstract: Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of… read more here.
Keywords: tumor informed; informed tumor; breast cancer; detection ... See more keywords
Utility of tumor-informed circulating tumor DNA in the clinical management of gastrointestinal malignancies.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo-21-484
Abstract: Background Gastrointestinal (GI) malignancies represent a heterogeneous group of diseases. Traditional tumor markers, though part of standard-of-care, lack sensitivity and specificity. Tumor-informed circulating tumor DNA (ctDNA) assay-based molecular residual disease assessment as well as recurrence… read more here.
Keywords: tumor; circulating tumor; tumor informed; tumor dna ... See more keywords